BioCentury | Oct 23, 2020
Product Development

Fresh $20M allows Azura to move lead candidate into pivotal testing for major cause of dry eye

With a new $20 million financing that doubles what the company has raised to date, Israel’s Azura will be able to advance its lead program into a registrational study to address a major cause of dry...
BioCentury | Jul 31, 2020
Distillery Therapeutics

Targeting the metabolic enzyme DGAT1 to treat glioblastoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer DGAT1 inhibition could treat glioblastoma multiforme (GBM) by promoting fat catabolism. Levels of triglycerides and lipid droplets were higher in postmortem brain tissue from GBM patients than individuals without...
BioCentury | Jan 10, 2020
Company News

Lilly bolsters atopic dermatitis arsenal via $1.1B Dermira deal, gaining Dupixent challenger

Via its $1.1 billion takeout of Dermira on Friday, Eli Lilly added to its late-stage pipeline an atopic dermatitis therapy that could challenge Dupixent. The price -- $18.75 per share -- is a premium of...
BioCentury | Nov 13, 2019
Company News

Nov. 12 Company Quick Takes: Clinical hold for Solid Bio; plus Foamix-Menlo, Chi-Med, RegeneRx and Actelion

Solid Bio shares sag on news of latest clinical hold FDA has placed a clinical hold on the Phase I/II IGNITE DMD study of gene therapy SGT-001 from Solid Biosciences Inc. (NASDAQ:SLDB) after one of...
BioCentury | Oct 7, 2019
Company News

Oct. 7 Company Quick Takes: Editas-MaxCyte, Goldfinch-Takeda, Prometheus-Takeda, DBV and Galderma

Editas licenses MaxCyte tech to develop engineered cell medicines Editas Medicine Inc. (NASDAQ:EDIT) licensed non-exclusive clinical and commercial rights to Flow Electroporation technology and ExPERT instruments from MaxCyte Inc. (LSE:MXCT) to develop engineered cell medicines,...
BioCentury | Sep 9, 2019
Company News

Management tracks: Coles to lead Cerevel; plus Genfit, Jubilant, Paratek, Mogrify, Dementia Discovery Fund and Ayala

Cerevel Therapeutics LLC (Boston, Mass.) hired Tony Coles as CEO. Coles is Cerevel’s executive chairman as well as the co-founder and executive chairman of neurodegeneration company Yumanity Therapeutics LLC (Cambridge, Mass.), where he was until...
BioCentury | Jul 25, 2019
Distillery Therapeutics

Inhibiting PARP for pathologic vascular calcification

DISEASE CATEGORY: Cardiovascular INDICATION: Cardiovascular PARP inhibition could treat pathologic vascular calcifications. In patients with carotid artery disease, sites of calcification within atherosclerotic plaques and blood vessel tunica media had higher extranuclear deposition of PARP-synthesized...
BioCentury | Jul 20, 2019
Emerging Company Profile

China Ophthalmology Focus eyes Asia market

Spun out from Lee’s in May and aiming for its first NDA submissions next year, China Ophthalmology Focus is already looking ahead to a Hong Kong IPO and an expansion into other Asian markets with...
BioCentury | Jul 17, 2019
Company News

July 17 Company Quick Takes: FDA approves Merck antibiotic combo; plus PureTech, Inovio, BiomX

FDA approves Merck's antibiotic combo FDA approved Merck's Recarbrio imipenem/cilastatin/relebactam antibacterial to treat adults with complicated urinary tract infections (cUTIs) and complicated intra-abdominal infections (cIAIs). Unlike most of its peers, Merck & Co. Inc. (NYSE:MRK)...
BioCentury | Jun 29, 2019

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
Items per page:
1 - 10 of 750